The Zhitong Finance App learned that Biohaven (BHVN.US) said on Wednesday that its experimental depression drug failed to meet the main goals in a mid-term trial. This is the latest in a series of testing and regulatory setbacks the company has experienced this year. The company's stock price fell 16% in after-hours trading, and the cumulative decline since this year has exceeded 70%.

The Zhitong Finance App learned that Biohaven (BHVN.US) said on Wednesday that its experimental depression drug failed to meet the main goals in a mid-term trial. This is the latest in a series of testing and regulatory setbacks the company has experienced this year. The company's stock price fell 16% in after-hours trading, and the cumulative decline since this year has exceeded 70%.